TICKERNERD
Menu
STOKSTOKHealthcare · Biotechnology

STOK Stock Forecast: Stoke Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$32
+2.83% on the day

The 14 Wall Street analysts covering Stoke Therapeutics, Inc. hold a median 12-month price target of $44 — +36.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$2.1B
Ticker Nerd rank
55 / 100
Median analyst target
$44
Analysts covering
14
Total return, dividends reinvested
1W
+3.3%
1M
+12.1%
YTD
+1.7%
1Y
+64.1%
From 52W high
−15.8%
From 52W low
+71.1%
$19
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STOK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Stoke Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Accruals
72
Quality
65
Value
62
Volatility
60
Issuance
43
Revisions
43
Size
36
Growth
17

Momentum (94): The shares have been drifting up relative to others.

Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STOK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STOK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26STOKHigh $60Median $44Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $35Median $44High $60

The green dot is the last close — the median target sits +36.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Aug 2026Canaccord GenuityMaintainsBuy$60 → $58
4 Aug 2026Chardan CapitalMaintainsBuy$35
4 Aug 2026GuggenheimReiteratesBuy$60
4 Aug 2026WedbushMaintainsOutperform$38 → $40
13 July 2026Goldman SachsInitiatesBuy$44
13 July 2026Goldman SachsInitiatesBuy—
11 May 2026BTIGReiteratesBuy—
20 Mar 2026Canaccord GenuityMaintainsBuy—
19 Mar 2026BTIGReiteratesBuy—
18 Mar 2026Chardan CapitalMaintainsBuy—
18 Mar 2026WedbushMaintainsOutperform—
17 Mar 2026NeedhamMaintainsBuy—
17 Mar 2026WedbushMaintainsOutperform—
24 Feb 2026Wolfe ResearchInitiatesOutperform—
12 Jan 2026WedbushMaintainsOutperform—
5 Jan 2026Canaccord GenuityMaintainsBuy—
5 Jan 2026Chardan CapitalMaintainsBuy—
15 Dec 2025HC Wainwright & Co.MaintainsBuy—
5 Nov 2025BTIGReiteratesBuy—
5 Nov 2025Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STOK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

STOK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

Stoke Therapeutics, Inc. (STOK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
48.8×

Cheaper than 15% of US stocks

Price / sales
75.5×

Cheaper than 5% of US stocks

Price / book
5.8×

Cheaper than 19% of US stocks

EV / EBITDA
−8.1×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
−32.5%

Higher than 8% of US stocks

Earnings growth (YoY)
−32.5%

Higher than 15% of US stocks

Gross margin
—
Operating margin
−701.7%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−61.1%

Higher than 18% of US stocks

Return on assets
−35.9%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

STOK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
STOKStoke Therapeutics, Inc.$2.1B
55
BHVNBiohaven Ltd.$2.0B
24
PVLAPalvella Therapeutics, Inc.$2.0B
31
ZBIOZenas BioPharma, Inc.$2.0B
25
XNCRXencor, Inc.$2.0B
83
ZYMEZymeworks, Inc.$2.1B
72
SRPTSarepta Therapeutics, Inc.$2.0B
72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Stoke Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STOK news & analysis

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire · 18 Aug 2026neutral

Stoke Therapeutics announced that, effective August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven individuals as inducement grants under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement stock-option grants represent a routine equity-compensation action tied to hiring that STOK watchers may track for corporate-governance and share-dilution purposes.

Stoke Therapeutics' Dravet Trial Tops Enrollment Target With Zero Dropouts

MarketBeat · 18 Aug 2026positive

Stoke Therapeutics reported that its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding the target of 150, with no patient discontinuations reported to date.

Why it matters — Strong enrollment and zero dropouts in the pivotal trial suggest steady study progress for a key pipeline candidate in Stoke's development program.

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Seeking Alpha · 5 Aug 2026positive

The article highlights progress on zorevunersen for SCN1A Dravet Syndrome, with an FDA meeting expected in H2 2026, a rolling NDA submission in Q1 2027, and phase 3 EMPEROR data in Q3 2027. It also notes the advancement of STK-002 for autosomal dominant optic atrophy in the phase 1 OSPREY study.

Why it matters — A STOK watcher would care because these upcoming clinical and regulatory milestones for zorevunersen and STK-002 reflect the continued development and broader potential of the company's pipeline.

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Business Wire · 5 Aug 2026neutral

Stoke Therapeutics announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference. The company is developing zorevunersen as a potential disease-modifying treatment for Dravet syndrome.

Why it matters — A STOK watcher would care because the company's leadership is set to present at a major investment conference, offering an opportunity to share updates on its development program.

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Benzinga · 4 Aug 2026neutral

Stoke Therapeutics reported mixed second-quarter results on Monday. Following the release, analysts revised their forecasts for the company.

Why it matters — A STOK watcher would care because analyst forecast revisions after quarterly results can shift expectations for the company's performance.

FAQ

Frequently asked questions about STOK stock

What is the STOK stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Stoke Therapeutics, Inc. have a median 12-month price target of $44, with estimates ranging from $35 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STOK stock a buy right now?

Of the 14 analysts covering Stoke Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stoke Therapeutics, Inc. 55 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STOK?

As at 22 Aug 2026, Stoke Therapeutics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will STOK stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +36.3% from the last close, and Ticker Nerd's factor model ranks Stoke Therapeutics, Inc. 55 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STOK stock forecast for 2030?

No analyst covering Stoke Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STOK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $60 over the next 12 months.

How has STOK stock performed over the past year?

Stoke Therapeutics, Inc. returned +64.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Stoke Therapeutics, Inc. do?

Stoke Therapeutics Inc. is a biotechnology company focused on developing RNA-based medicines to treat the underlying causes of severe genetic diseases.

What is the latest news on STOK?

The most recent item we track (Business Wire, 18 Aug 2026): "Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)". Stoke Therapeutics announced that, effective August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven individuals as inducement grants under Nasdaq Listing Rule 5635(c)(4).

Company

About Stoke Therapeutics, Inc.

Stoke Therapeutics Inc. is a biotechnology company focused on developing RNA-based medicines to treat the underlying causes of severe genetic diseases. It employs its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform, which uses antisense oligonucleotides to upregulate protein expression from healthy genes, compensating for mutated copies in conditions known as autosomal dominant haploinsufficiencies. This approach targets tissues including the central nervous system, eye, kidney, and liver. The company's lead investigational medicine, zorevunersen (STK-001), addresses Dravet syndrome, a severe genetic epilepsy characterized by frequent seizures, intellectual disability, and developmental delays, with ongoing Phase 3 clinical studies in collaboration with Biogen. Additional efforts explore TANGO ASOs for autosomal dominant optic atrophy and other severe diseases. Stoke Therapeutics Inc. maintains a pipeline aimed at pioneering disease-modifying therapies. Founded in 2014 and headquartered in Bedford, Massachusetts, the company drives innovation in precision medicine for genetic disorders.

CEO Mr. Ian F. Smith A.C.A., C.P.A. · 170 employees · United States · https://www.stoketherapeutics.com